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Abstract Within the field of cancer research, focus on the
study of minimal residual disease (MRD) in the context of
carcinoma has grown exponentially over the past several
years. MRD encompasses circulating tumour cells
(CTCs)—cancer cells on the move via the circulatory or
lymphatic system, disseminated tumour cells (DTCs)—
cancer cells which have escaped into a distant site (most
studies have focused on bone marrow), and resistant cancer
cells surviving therapy—be they local or distant, all of
which may ultimately give rise to local relapse or overt
metastasis. Initial studies simply recorded the presence and
number of CTCs and DTCs; however recent advances are
allowing assessment of the relationship between their
persistence, patient prognosis and the biological properties
of MRD, leading to a better understanding of the metastatic
process. Technological developments for the isolation and
analysis of circulating and disseminated tumour cells
continue to emerge, creating new opportunities to monitor
disease progression and perhaps alter disease outcome.
This review outlines our knowledge to date on both mea-
surement and categorisation of MRD in the form of CTCs
and DTCs with respect to how this relates to cancer out-
comes, and the hurdles and future of research into both
CTCs and DTCs.
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Introduction
Breast cancer is the most commonly diagnosed female
cancer with the exclusion of skin cancers. It is the second
highest cause of cancer mortality in women behind lung
cancer, and carries a lifetime incidence risk of 1 in 8 [1].
Importantly, the proportion of females having survived
cancer is greatest for breast cancer, accounting for nearly
half of all cancer survivors [2]. This presents an issue with
respect to potential relapse and in turn highlights the
importance of MRD. Currently, metastatic cancer is
incurable and thus metastasis accounts for the majority of
deaths associated with cancer. It is well established that the
metastatic process is very complex and numerous hypo-
thetical models have been proposed to explain the oft-ter-
med ‘metastatic cascade’ of events, which documents the
various requirements of malignant cells escaping the pri-
mary tumour and establishing metastases elsewhere [3, 4].
Despite the expanse of knowledge pertaining to the cas-
cade, many exact details are not fully elucidated. It is
known that metastases occur preferentially in specific dis-
tant sites depending on the organ of origin, such as bone
and selected visceral organs for breast cancer [5]. Recur-
rence can also occur at the primary tumour site even after
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complete tumour resection with apparently clear surgical
margins. Recurrence or metastasis may occur after many
years, for example women with hormone receptor positive
breast cancer, although having a relatively favourable
overall prognosis, still exhibit an elevated annual hazard of
recurrence over many years [6]. Comparatively, ‘triple
negative’ breast cancers lacking hormone receptors (HRs)
and human epidermal growth factor receptor 2 (HER2)
typically have less treatment options and a higher recur-
rence rate and thus poorer outcome [7]. However, the
majority of recurrences occur in the first 5 years after
diagnosis; so long term survivors are more likely to be
‘cured’. This should be considered alongside the fact that
old autopsy studies have demonstrated the presence of
cancers in people who had otherwise been undiagnosed [8],
and that occult metastases undetectable by conventional
imaging have been demonstrated in breast cancer patients
[9]. This, alongside understanding the metastatic process, is
the fundamental basis for the need to study MRD.
Currently an area of great interest is the characterisation of
cells that are able to escape from the primary tumour and
survive in the peripheral blood as CTCs, or in the bone
marrow as DTCs, as is the mechanisms by which they are
able to achieve these feats. It has been demonstrated in a
model system that around amillion cells are shed per gram of
primary breast tumour tissue every day but almost all of these
are very efficiently eliminated from the circulation within
minutes [10]. However, in animal models it has been shown
that approximately 2.5 % of cells that are shed are able to
survive as micrometastases and approximately 0.01 % can
progress to form macrometastases [11, 12]. The question
must therefore be asked; what factors give this very small
minority of cells the ability to survive and prosper?
This review examines mechanisms of metastasis and the
respective role(s) of CTCs and DTCs using breast cancer as
a specific example, which in itself is not one disease as is
reflected by sub-classification based on both histopatho-
logical and molecular characteristics that have been
reviewed in depth already [13, 14]. However, there are
mechanisms shared with other types of carcinoma and are
occasionally discussed here in the context of CTCs/DTCs.
We include features of both CTCs/DTCs and aspects of the
metastatic sites that enable the dissemination, survival and
proliferation of the very small subpopulation of cancer
cells that are ultimately able to produce metastases.
Understanding the metastatic cascade
It is known that cancer cells are typically heterogeneous. This
has been demonstrated in vitro and in vivo both molecularly
[15–18] and proteomically [19–21], and underpins the asso-
ciated phenotypic heterogeneity of cancers. For example,
evenwithin the same breast cancer and in cases ofmetastases,
there appears to be a subset of putative ‘cancer stem cells’
(CSCs) that are intrinsically highly resistant to chemotherapy
and/or radiotherapy and that are involved in the crucial step of
cancer dissemination [22–24]. This heterogeneity has been
attributed to the widely accepted clonal evolution theory in
cancer, which describes a sequential accumulation of
favourable mutations over time that may either be key drivers
or potentially beneficial passengers in cancer development.
Aside from the CSC theory discussed later, recent work has
presented a new idea in the context of colorectal cancer that
may have application in other carcinomas. Sottoriva et al. [25]
have proposed the big bang model that explains intra-tu-
moural heterogeneity (ITH) as being a consequence of both
broad clonal and more isolated sub-clonal mutations within a
tumour during early development. The emphasis on these sub-
clonalmutations occurring early is of importancewith respect
to ITH, as it is suggested that they are more likely to mix and
then spatially spread as the tumour grows. Thus, timing is
considered of importance in this model as the prevalence of
these sub-clonal mutations in a given tumour is proposed to
occur not because theyprovideda selective advantage, but as a
consequence of when they arose. In the context of colorectal
cancer this idea of many sub-clonal mutations occurring in
parallel early onmakes sense given the abundance and highly
active nature of proliferating cells within the crypts of Lie-
berkuhn, however other tissues do not share this similar
architecture/behaviour and therefore the applicability of the
big bang model in other cancers remains to be seen. It is
generally accepted and understood that there is a progression
of events that must occur for a primary tumour in the breast to
becomeestablished at a distantmetastatic site. Initially there is
an activation of signalling pathways that control tumour
cytoskeletal dynamics, the turnover of cell–matrix and cell–
cell junctions and subsequently, active tumour cell migration
into the surrounding tissue [26]. Malignant cells must then
intravasate into blood or lymphatic vessels, penetrate base-
ment membranes and endothelial walls, survive whilst in the
circulation, evade immune defences and other cell death
mechanisms such as apoptosis, and travel to a secondary site
[27–29]. At this point they must extravasate into the distant
tissue and regain or enhance cellular characteristics that allow
for anchorage, communication, survival and adaptation into
the new microenvironment, in turn promoting mechanisms
that enable the proliferation of a cohesivemass of tumour cells
which will ultimately become an overt macrometastasis [29].
Seed and soil hypothesis
CTCs are ‘in transit’ cancer cells arising initially from the
primary tumour, but later from micrometastases (when
there is no clinical evidence of metastasis) and from overt
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metastases. CTCs, which have been predominantly studied
and observed in the vascular bloodstream rather than
lymphatics, were originally discovered in 1869 by Aus-
tralian physician Thomas Ashworth [30]. Shortly there-
after, in 1889, Stephen Paget observed that the process of
metastasis did not seem to occur by chance and proposed
the ‘seed and soil’ hypothesis [31]. The ‘seed’, or CTC as
we currently know it to be, would be able to grow and
establish a new tumour only if able to locate the appro-
priate ‘soil’ in which to propagate. Paget based this
hypothesis on the post-mortem examination of 735 breast
cancer patients, where he noted that there was a distinct
preference for metastatic sites such as bone and selected
visceral organs [31].
This hypothesis has subsequently been repeatedly
demonstrated with ‘seed’ cells arising from specific tumour
types showing a strong preference for the ‘soil’ of specific
metastatic sites [32, 33]. It is thought that tumour cells can
express particular proteins such as parathyroid-hormone-
related peptide (PTHrP) [34], or chemokine receptors such
as CXC chemokine receptor type 7 (CXCR7) [35] and CXC
chemokine receptor type 4 (CXCR4) [36], which help
direct cancer cells toward specific sites like the bone.
Additionally, the survival and propagation of tumour cells
at a specific secondary site may be determined by
chemokines produced at the site of dissemination [22].
Husemann et al. [37] demonstrated early dissemination of
cancer cells into the circulation and bone marrow in the
context of patients with ductal carcinoma in situ (DCIS)
and a model of atypical ductal hyperplasia (ADH), the
latter being unexpected as dissemination from ADH has
not been seen in patients. They proposed that surgical
removal of the primary lesion at very early time points may
deprive such early-disseminated cancer cells from sys-
temically-acting factors important for outgrowth and con-
sequently account for dormancy of such cells. They also
suggest that primary tumours may secrete factors that
prepare the pre-metastatic niche (or ‘soil’) and foster early
cancerous colonies. It has been demonstrated by Kaplan
et al. that tumour-specific pre-metastatic sites contain bone
marrow-derived haematopoietic progenitor cells that
express vascular endothelial growth factor (VEGF) recep-
tor 1 (VEGFR1) [38, 39]. Work by Kallergi et al. [40]
revealed that CTCs in most of the metastatic patients they
assessed exhibited an upregulation of VEGF. As noted
earlier, the same group subsequently found that a TWIST
mediated epithelial–mesenchymal transition (EMT) also
drives an upregulation of VEGF [41]. Therefore the pres-
ence of VEGFR1 at the pre-metastatic site may be a crucial
factor in the homing of CTCs to bone marrow and the
eventual establishment of DTC deposits. This is supported
by Kaplan et al. [38], who demonstrated that antibody-
mediated inhibition of VEGFR1 function, or the removal of
VEGFR1 cells from the bone marrow, abrogated the for-
mation of pre-metastatic clusters and prevented tumour
metastasis to bone. It was also shown that VEGFR? cells
express integrin a4b1 and that fibronectin is up-regulated in
resident fibroblasts by tumour-specific growth factors.
Fibronectin is a ligand of integrin a4b1 and increased
expression provides a permissive niche for incoming
tumour cells [38]. Interestingly, it has subsequently been
shown that a4b1 osteoclast progenitors respond to VCAM-
1 expression by micrometastases, enabling disease pro-
gression in bone [42]. Therefore it may be that one critical
cell-type is responsible for both metastatic homing and
expansion in bone. Similar studies by Gao et al. [43]
support a role for bone marrow-derived macrophages
conditioning the metastatic niche through the secretion of
the proteoglycan versican, which in turn sequesters TGFb
and causes reversion from a mesenchymal phenotype
(mesenchymal–epithelial transition; MET) in CTCs as they
become DTCs.
It is now well established that CTCs can arise from the
primary tumour, carry the malignant features of said pri-
mary tumour [44], are able to survive in the circulation,
have the ability to extravasate and that at least in some
patients, a small proportion of them are ultimately able to
establish metastases at a distant site, whereby the site itself
has been subjected to metastasis-optimising conditions by
native cell populations prior to the arrival of the dissemi-
nating cancer cell.
Local mechanisms of disease relapse
Tumour self-seeding
In addition to establishing metastatic tumours at secondary
sites, it has been demonstrated experimentally that CTCs
also have the ability to return to the site of tumour origin.
Kim et al. [45] were the first researchers to demonstrate
this and determined that CTCs (from fluorescently tagged
populations) were able to colonise an untagged recipient
mammary fat pad (MFP). The source of the CTCs in some
instances were from an opposing MFP that had a fluores-
cently labelled primary tumour growing (of the same cell
line), or from fluorescently tagged cells injected directly
into the circulation. The study describes an increased
capacity for metastatic progeny to be able to re-seed the
primary tumour, which coincides with observations by
Braun et al. [46] that patients with detectable DTC are at
significantly greater risk of local relapse. Interestingly,
fluorescently tagged cells from the ‘parental tumour’ that
had successfully re-seeded the ‘recipient’ tumour were
isolated and determined to have a greater capacity for self-
seeding. Furthermore, the transcriptional profile of these
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‘seeder’ cells shared similar expression patterns as some of
their metastatic counterparts. Mechanisms investigated
included the chemo-attractive ability of interleukin 6 (IL-6)
and interleukin 8 (IL-8), as well as the function of fascin
actin-bundling protein 1 (FSCN1), matrix metallopro-
teinase-1 (MMP1) and CXC chemokine ligand 1 (CXCL1)
using the MDA-MB-231 metastatic breast cancer (MBC)
cell line model. Therefore ‘self-seeding’ essentially
involves attraction of CTCs back to the primary tumour
in situ and reflects an ability of CTCs to extravasate and
infiltrate the established tumour. Since this publication by
Kim et al. [45], other work has been performed attempting
to further elucidate the mechanism of self-seeding [47] as
well as illustrating its occurrence in osteosarcoma [48].
Moreover, a string of review articles covering the topic of
tumour self-seeding also surfaced following the work
presented by Kim et al. These review articles, in con-
junction with the original work itself, suggest several
advantages for tumour self-seeding; (i) an increase in pri-
mary tumour growth rate, (ii) the promotion of local re-
growth and (iii) the ‘natural selection’ of more aggressive
CTC subpopulations that would have greater success at
colonising a distant site [22, 49–53]. Therefore this tumour
self-seeding process may in fact contribute to the charac-
teristics of CTCs/DTCs, that are still being elucidated and
could also be responsible in part for generating the sub-
populations of MRD that are more likely to metastasise
successfully. Furthermore, work pertaining to tumour self-
seeding has yielded data which could at least partly explain
observed associations with metastasis, such as; large
tumour size, anaplasia (the loss of differentiation and ori-
entation of cells to one another and the surrounding tissue
framework), and the hypervascularity of cancers with poor
prognosis [45].
Therapy resistant cells
Work originally investigating putative CSC populations
and their behaviour, as will be discussed separately, set the
groundwork towards investigations of subpopulations of
cancer cell that persist after therapy. A study in 2006
assessed MCF7 and MDA-MB-231 breast cancer cell lines
grown in 2D culture compared to CD44?ve/CD24-ve sub-
populations grown in mammosphere assays after exposure
to different amounts of radiation. Greater radioresistance
was observed in the subpopulation cultures as measured by
reactive oxidative species (ROS) and pH2AX. Further
assessment using MCF7 cells revealed that following
radiation exposure in 2D culture, non-adherent floating
cells were enriched for CD44?ve/CD24-ve while adherent
cells were not, and that these resilient cells had enhanced
Notch1 expression. This resilience was confirmed in 2008
by Fillmore et al. [54] who used a chemotherapeutic
approach on a larger number of breast cancer cell lines, but
who also performed xenotransplantation assays comparing
unsorted and CD44?ve/CD24-ve/ESA?ve sorted cells and
observed a much greater tumour initiating capacity in the
sorted subpopulation. In the same year, Li et al. [55] was
the first group to assess the CD44?ve/CD24-ve phenotype
in paired core biopsies from breast cancer patients under-
going neoadjuvant therapy, as well as mammosphere for-
mation capacity. In patients receiving conventional
therapy, the proportion of this subpopulation increased in
addition to the ability to form mammospheres. However,
there was no significant difference in patients receiving
lapatinib, and in fact there was a slight reduction. This
work was followed by Creighton et al. [56] who used a
similar paired biopsy approach in patients that received
letrozole or docetaxel neoadjuvant therapy and also
observed an increase in the CD44?ve/CD24-ve subpopu-
lation as well as mammosphere forming efficiency.
Importantly, they demonstrated via immunofluorescence
using clinical samples that this resilient subpopulation
consisted of hybrid epithelial–mesenchymal cells. Further,
that those resilient cells were enriched for mesenchymal
markers including FN1, MMP2, MMP3, FOXC2 (forkhead
box protein C2), VIM, and SNAI2. Since this work there
have been publications demonstrating that; (i) these
radioresistant cancer initiating cells can maintain self-re-
newal capacity and are in fact pushed out of quiescence
into an actively dividing state [57], (ii) that STAT1 inhi-
bition increases apoptosis post-radiation treatment in
CD44?ve/CD24-ve MCF7 sorted cells grown in 3D culture
[58], and (iii) downregulation of CD44 in this cancer ini-
tiating subpopulation increases susceptibility to doxoru-
bicin therapy [59]. Therefore there is evidence to indicate
that therapy resilient cells that remain as residual disease
are paradoxically being enhanced in their tumour initiating
capacity, and in turn a risk with respect to both local
tumour recurrence as well as distant metastasis.
Mechanisms of therapy resistance
Cancer cell resistance of chemotherapeutic agents and
radiation therapy have been described as falling into two
camps—multi-drug resistance and pan-resistance. While
there is overlap with respect to the mechanisms that form
the foundation of each process, they are considered as
being two distinctly different arms of therapy resistance.
The distinction between the two becomes apparent when
one considers the way in which resilience is conferred unto
the cell, and importantly, the nature of the resistance that
results.
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Multi-drug resistance
This is the concept most commonly thought of with regards
to therapy resistant cancer cells and revolves around five
key mechanisms; (i) drug transporters/efflux pumps, (ii)
modulation of apoptosis and senescence pathways by the
cancer cell, (iii) cell cycle effects, (iv) mechanical/
stochastic factors, and (v) CSC mediated—the latter is
discussed in a separate section with respect to EMT and
CTCs/DTCs. The ATP-binding cassette (ABC) membrane
transporter protein family has for some time been identified
as responsible for moving drug out of cancer cells. The
major player P-glycoprotein, encoded by the ABCB1/
MDR1 gene, has been shown to act on substrates such as
anthracyclines, taxanes, vinca alkaloids, and epipodophyl-
lotoxins [60]. However there are substrates that P-glyco-
protein acts poorly on, particularly large hydrophilic drugs
and nucleoside analogues. Other ABC family proteins aid
in acting on different substrates, such as ABCG2 which is
also known as breast cancer resistance protein (BCRP), and
acts on amphipathic drugs [61]. Recent work by Jang et al.
has demonstrated doxorubicin sensitisation of resilient
putative CSC subpopulations from MDA-MB-231, MCF7,
and MCF10A cell lines in vitro via downregulation of
ABCG2 as mediated by suppression of adenine nucleotide
translocator-2 (ANT2) with shRNA. Alteration of senes-
cence pathways makes logical sense in terms of maximis-
ing cancer cell longevity, for example by hijacking the
telomerase function of the cell as a means of avoiding
cellular aging [62]. Theoretically, manipulation of apop-
tosis pathways would also be of benefit given the fact that
therapy often acts to induce cell death due to excessive cell
damage, as indeed has been demonstrated in blood cancers
[63, 64]. Given that the vast majority of human cancers are
carcinomas, which are often devoid of a functional p53
pathway [65], then the role of apoptosis pathway modula-
tion becomes questionable and has indeed been demon-
strated to lack functional significance in breast cancer [66].
Conceptually, cell cycle affects are straight forward with
respect to cancer cell resilience. Many chemotherapeutic
agents and radiotherapy act to disrupt the cell cycle, for
example by induction of DNA damage or disruption of
microtubule formation needed to complete mitosis, and as
such these approaches inherently work best on actively
dividing cells. Therefore, cells in a state of quiescence that
are not actively dividing would remain unaffected [67].
The final aspect of drug resistance relates to physical
parameters that influence drug-target interaction and thus
resilience to treatment. If the drug cannot physically
interact with its target, then there can be no effect. This has
been shown in breast cancer patients who relapsed with
brain metastases that were being treated with an antibody
that does not cross the blood–brain barrier [68], or in
pancreatic ductal adenocarcinoma where drug penetration
is poor due to an extensive stromal envelope [69]. The key
overall feature of multi-drug resistance is that tumours
develop in a way that allows persistence in the face of
many, but not all therapies.
Pan-resistance
Pan-resistance has been described by Borst [70] as being
residual cancer disease that persists after initial therapy,
which returns in a far more aggressive manner that is
completely unresponsive to any treatment. The driving
force for pan-resistance is less well defined compared to
multi-drug resistance, however the mechanisms already
described pertaining to cell cycle effects and CSCs appear
to play a potential role. Borst [70] provides two other
explanations for pan-resistance, the first being superde-
fence—whereby the cells work overtime to keep all drugs
away from their target. The second is compensation—
which does not affect drug-target interaction but rather uses
other mechanisms to compensate as a consequence of said
interaction, such as activation of parallel pathways to those
targeted. Another explanation for the phenomenon of pan-
resistance lies in the work of Sharma et al. [71], who used
an in vitro model of non small cell lung cancer (NSCLC)
treated with an EGFR-targeting tyrosine kinase inhibitor to
generate drug-tolerant persisters (DTPs) with 100-fold
reduced drug sensitivity. When the DTP cells were grown
in the absence of drug they would regain sensitivity, and if
left in the presence of drug most would remain quiescent
but approximately 20 % of DTPs would resume normal
proliferation and were termed drug-tolerant expanded
persisters (DTEPs). The authors were able to restrict the
formation of DTPs/DTEPs through inhibition of the IGF-1
receptor, by inhibition of KDM5A demethylase, and
through use of histone deacetylase (HDAC) inhibitors. This
work has identified a chromatin-mediated reversible drug
tolerant state in residual cancer populations that may
account for pan-resistance.
Epithelial–mesenchymal transition
A critical step in the process of invasion and metastasis is
the phenotypic change in tumour cells known as EMT.
Three types of EMT have been described and reviewed;
type 1 EMT is associated with embryogenesis and devel-
opment and type 2 EMT pertains to wound healing, tissue
regeneration and organ fibrosis [72, 73]. Whilst these first
two are affiliated with highly regulated physiological pro-
cesses, type 3 EMT relates to the transformation of
epithelial cancer cells in relation to the process of metas-
tasis and is thus pathological [74]. It was reported by Boyer
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et al. [75] that the process of ‘cell scattering’, an essential
step in invasion and metastasis, involves at least two bio-
logical events; (i) cell–cell dissociation as a result of the
disruption of intercellular bonds and (ii) cell movement as
a result of rearrangement of cytoskeletal proteins and the
formation of new cell-substratum contacts. These events
appear to occur simultaneously or synchronously within
cells and lead to active cell migration. In normal cells there
is a requirement for the activation of a range of highly
controlled and spatio-temporally regulated signalling
molecules to trigger the changes seen during EMT, which
do not occur under normal circumstances. However, it is
proposed that in cancer cells, oncogenic activation of sig-
nalling molecules may result in a cell-autonomous EMT
process [75].
More than 95 % of primary breast cancers are of epithelial
origin [76]. Epithelial cells havea cobblestone appearance and
are firmly held in a relatively rigid structure through distinct
contact between cells, constituted by tight junctions, adherens
junctions, desmosomes and gap junctions (Fig. 1) [77].
E-cadherin is a widely studied transmembrane glycoprotein
which in epithelial structures is essential for maintaining
stable tissue architecture through cell–cell adhesion [78]. The
intracellular domain of E-cadherin binds with catenins that in
turn are linked to the actin cytoskeleton [79]. It is these
interactions, as well as the homodimerisation occurring
between the extracellular domains of E-cadherin molecules,
which are essential for stable cell–cell structure [79]. Specific
integrins also anchor epithelial cells to constituents of the
extracellular matrix (ECM) such as laminins, fibronectin and
collagen [80–82]. However, during EMT cell–cell adhesions
involving E-cadherin in adherens junctions, occludins and
claudins in tight junctions and desmoplakin in desmosomes,
along with the affiliated apico-basal polarity, are lost as cells
take on mesenchymal characteristics [73]. The cells become
more elongated or ‘spindle-like’, flexible, mobile and there-
fore potentially invasive (Fig. 1) [77].
Mesenchymal cells have a less defined and structured
organisation, lacking the apico-basal polarity of epithelial
cells or a guiding basal lamina, and are thus subject to changes
in the actin and intermediate filament cytoskeletal framework
[72]. During EMT there is an increase in the secretion of
proteolytic enzymes, which results in degradation of the
ECM, mediated by matrix metalloproteinases (MMPs) and
the urokinase plasminogen activator (uPA) system, thus
enabling the cells to invade surrounding stroma and tissues
[83]. It has been shown that activation of the uPA system is
associated with a poor prognosis in breast cancer [84, 85].
More recently, the mesenchymal-like phenotype was also
associated with decreases in sensitivity to current anti-cancer
therapies including cytotoxic and molecular targeted agents
[86]. The overall effect is a significant improvement in the
metastatic efficiency of these cancer cells [87, 88].
In addition to the characteristic loss of expression of
E-cadherin and epithelial-associated cytokeratins (CKs), EMT
also involves an increase in the expression of vimentin,
N-cadherin, the secretion of MMP enzymes and an accompa-
nying increase in the expression of transcription factors (TFs)
such as TWIST, SNAIL and snail homolog 2 (SLUG) that pro-
mote the mesenchymal phenotype. Korsching et al. [89]
showed that vimentin expression correlatedwith tumour grade,
the expression of alpha smoothmuscle actin (ASMA) and also
with the expression of genes including the epidermal growth
factor receptor (EGFR), cytokeratin 5 (CK5) and cytokeratin
10 (CK10), which are all implicated in basal breast cancer.
Despite questioning the degree to which EMT is responsible
for the vimentin expression observed in invasive breast can-
cers, they concluded that vimentin expression was evidence of
the final step of de-differentiation in tumours and was associ-
ated with invasion. The extent and nature of vimentin expres-
sion in breast cancer has previously been reviewed [90]. Sarrio
et al. [91] have shown a relationship between a range of basal/
mesenchymal markers and poorer outcome in breast cancers.
Willipinski et al. [92] utilised a large series ([2200) of breast
cancers to demonstrate that loss of CK and ectopic vimentin
expression were significantly associated with a higher tumour
grade, highmitotic index, andnegativeoestrogen/progesterone
receptor (ER/PgR) status, and significantly related to clinical
outcome in univariate analyses.
Dabbs et al. [93] recently revisited the use of E-cadherin
immunohistochemistry (IHC) with respect to lobular breast
cancers. The fact that lobular breast cancers either have poor
E-cadherin expression or are completely devoid of it was
confirmed in this work, yet histologically these tumours
maintain an epithelial appearance. Moreover, an extensive
screen of lobular breast cancer transcriptomes recently could
not show any evidence for increased EMT in these cancers,
despite the defining lack of the epithelial gate-keeper E-cad-
herin [94]. Alternative cadherins such as R-cadherin may be
acting as the primary cell–cell adhesion mediator [95].
Additionally, it is apparent that the functional natureof a given
cadherin varies depending on the biological context [96, 97].
Therefore, what constitutes a definitive EMT in cancer
becomes individualistic, as it is clear that the classic EMT
parameters do not always apply due to the likely presence of
an intermediate or hybrid phenotype [98]. While the lack of
E-cadherinmay focally pre-dispose lobular breast cancer cells
to EMT, it does not globally cause an EMT manifestation.
Epithelial–mesenchymal transition in MRD
Given that research has concentrated increasingly on EMT
in metastasis, the role of EMT in MRD has been a rela-
tively recent focal point. Hence there have been a number
of publications from various research groups reviewing
526 Clin Exp Metastasis (2016) 33:521–550
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aspects of EMT in CTCs/DTCs [99, 100]. The first paper
assessing E-cadherin status in MRD appears to have been
performed by Funke et al. [101] in 1996. This study used
IHC staining for CK18 and E-cadherin in the bone mar-
row of breast and gastric carcinoma patients. They found
individual CK18?ve cells to be present as well as small
clusters (2–9 cells) and larger clusters ([10 cells). Analysis
of E-cadherin status revealed DTCs to be positive, nega-
tive, or heterogeneous in their E-cadherin expression.
Specifically, breast DTCs tended to be heterogeneous with
a relatively even number of E-cadherin positive and neg-
ative patients, whereas almost all analysed gastric carci-
noma patients were negative with the exception of a single
heterogeneous case. While there was no overall statistical
indication of a trend for E-cadherin negativity in lone
DTCs and positivity in DTC clusters, it was noted that 3 of
4 patients with homogeneous E-cadherin positivity had
large DTC clusters in bone marrow. More recently, the
number of original research articles attempting to test the
EMT hypothesis in MRD is increasing. One of the earliest
papers looking at EMT in CTCs/DTCs observed an EMT-
like gene expression signature in breast cancer cells puri-
fied from pleural effusions using anti-epithelial cell adhe-
sion molecule (EpCAM) antibody MOC-31-conjugated
immuno-magnetic beads [36]. Microarray analysis was
performed and revealed that the cells purified from pleural
effusions were divided into two distinct subgroups that
were termed ‘EP1’ and ‘EP2’. Some genes upregulated in
the EP1 group were associated with the epithelial pheno-
type and included CKs, microtubule associated proteins,
genes involved in cell–cell adhesion, cell survival and
proliferation. In particular, the Ets-1 TF known to activate
metastasis-associated molecules was selectively upregu-
lated. Within the EP2 group genes associated with the
promotion of an aggressive mesenchymal phenotype and
EMT were upregulated and included MMPs, integrins,
vimentin and CXCR4. The Willipinski et al. [92] study
mentioned above also used protein-based assays to assess
cell lines established from the DTCs of breast cancer
patients. They found a loss of several epithelial-associated
CK proteins as well as a gain of vimentin in these DTC cell
lines when compared to MCF-7 and MTSV-1.7 reference
Fig. 1 Epithelial–mesenchymal plasticity (modified from Thiery and Sleeman [77]); a representative diagram on the roles of epithelial–
mesenchymal transition, mesenchymal–epithelial transition, and associated markers with respect to changes in cell morphology and behaviour
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cell lines [92]. The approach of utilising DTC cell lines for
the analysis of the mesenchymal marker vimentin, among
other markers, in MRD was originally published by Putz
et al. [102] in 1999. This was expanded upon by a group
that isolated DTCs from the bone marrow of breast cancer
patients and using a PCR based assay found an upregula-
tion of the E-cadherin transcriptional repressor TWIST1
[103]. Another study assessing EMT in CTCs intentionally
used negative selection only as their method of CTC
purification and observed the overexpression of at least one
of the following EMT promoting transcription factors;
TWIST1, SNAIL1, SLUG, zinc finger E-box-binding
homeobox 1 (ZEB1) and FOXC2 in 15.4 % of breast
cancer patients by qRT-PCR [104]. In the context of
prostate cancer, CTCs were assessed by fluorescent in situ
hybridisation (FISH) analysis and genomic imbalances in
breast cancer gene 1 (BRCA1) were observed with a more
advanced disease state. Further, these genetically aberrant
CTCs were found to be vimentin positive by immunocy-
tochemistry (ICC) staining [105]. Indeed, it has been
shown that increased expression of vimentin in primary
breast tumours is correlated with poor prognosis [106].
Additional studies have also reported on the expression of
vimentin in human DTC cell lines [107] as well as in CTCs
from clinical [41, 108] and mouse model blood samples
[109].
More recently, published work attempting to assess
EMT in CTCs/DTCs has expanded to include markers that
are said to be typical of breast CSC-like cells (BCSC)
[110–112]. These apparently mesenchymal BCSC are
thought to be able to establish new distant tumour colo-
nies as a result of their stem-like properties that enable the
differentiation and generation of the various cell pheno-
types observed in a heterogeneous tumour mass [113]. A
couple of papers focusing on these aspects looked
specifically at CTCs in early stage and MBC patient’s
post-systemic therapy using PCR based assays [41, 114].
The first applied the commercially available AdnaTest
and found an upregulation of the EMT promoting markers
TWIST1, v-akt murine thymoma viral oncogene homolog
2 (Akt2) and phosphatidylinositide 3-kinase alpha
(PI3Ka), in addition to the BCSC marker aldehyde
dehydrogenase 1 (ALDH1) [114]. This work has been
more recently complemented by Kallergi et al. [41] who
demonstrated that VEGF, hypoxia-inducible factor 1-al-
pha (HIF-1a) and phosphorylated protein kinase B (pAkt)
are expressed on CTCs in most MBC patients. Further,
they showed that TWIST and vimentin are expressed on
CTCs in both early stage and MBC [41]. Whilst TWIST
downregulates the expression of E-cadherin, it also
increases the transcription of the protein kinase B (Akt),
which is known to inhibit apoptotic processes. It has been
demonstrated that binding of TWIST to the Akt promoter
and the upregulation of Akt results in resistance to pacli-
taxel [115]. An RT-PCR assay was further used to show
that the proportion of ALDH1 positive CTCs was higher
in more advanced breast cancer patients and correlated
with vimentin and fibronectin expression [116]. These
gene expression profiles may have very important impli-
cations in clinical practice, where largely epithelial
markers are used in the commercially available CTC
assay devices that rely on marker detection. In an inter-
esting published letter, it was outlined that in patients
whose CTC numbers were assessed, a greater proportion
of patients were positive for CTCs when their cancer was
determined as either being HER2 overexpressing or triple
negative at diagnosis when compared to patients with
luminal type cancer [117]. This may be reflective of breast
cancer cell lines that are categorised into these respective
molecular subtypes, as triple negative cell lines for
example tend to fall into the Basal A and Basal B sub-
groups which frequently display mesenchymal and
tumour initiating properties [118].
Mesenchymal–epithelial transition
Whilst EMT/mesenchymal markers have been demon-
strated on CTCs and DTCs, it has also been observed that
human breast cancer metastases in liver, lung and brain
often express higher levels of E-cadherin relative to the
primary tumour and hence can be ‘more epithelial’ in
nature [119, 120]. In addition to membranous E-cadherin
promoting cell–cell adhesion, this epithelialisation has
been attributed to the ability of the E-cadherin cytoplasmic
domain to bind b-catenin, a-catenin and p120. This not
only links the adhesion molecule to the actin cytoskeleton,
but prevents nuclear localisation of b-catenin and in turn
LEF-1/TCF mediated transcriptional activation of the Wnt
signalling pathway [121], which has been demonstrated to
promote an aggressive mesenchymal phenotype in cancer
[122]. This phenomenon is also observed in other cancers
and their metastases [123, 124], indicating that MET, may
play an important role in the establishment of
macrometastases. Indeed, it is suggested that the mes-
enchymal properties of CTCs and DTCs are insufficient for
optimal malignant behaviour and in fact the ability to
transition from an epithelial to a mesenchymal phenotype
and then back to an epithelial state is an important deter-
minant of aggressive metastatic behaviour [125]. Arm-
strong et al. report that the preponderance of MET events
among lung metastases in rats bearing AT3 rat prostate
adenocarcinoma tumours suggested an important func-
tional relationship between the capacity to revert to a more
epithelial state and metastatic growth in the lung par-
enchyma [126]. Recent studies have further illustrated the
528 Clin Exp Metastasis (2016) 33:521–550
123
importance of MET in metastasis [127, 128] and others
have shown that the EMP cycle can endow a unique gene
expression profile on carcinoma cells, opening up new
therapeutic avenues [129, 130]. The dynamic ability of
cells to move across a spectrum of epithelial and mes-
enchymal states, as opposed to undergoing a one-way
transition, is what we term epithelial–mesenchymal plas-
ticity (EMP), an all-encompassing term which perhaps
more accurately describes the variable nature of this axis in
CTCs, DTCs, and the process of metastasis [131].
It is important to note that as implied by the concept of
EMP, there exists intermediate states whereby cells can
express both epithelial and mesenchymal markers to
varying degrees and these are very likely to be more
commonly observed than complete epithelial or mes-
enchymal states in the context of MRD. Some of the
studies previously discussed have proposed the concept of
an intermediary EMP phenotype in cancer, but the study
conducted by Creighton et al. [56] was the first to visually
demonstrate the phenomenon. While this study focused on
residual breast tumour cells following treatment, the
enrichment of mesenchymal and putative BCSC markers
has also been observed in CTCs of breast cancer patients
[132]. Recent work by Yu et al. [133] demonstrated both
rare primary tumour cells and highly enriched CTC sub-
populations that simultaneously expressed both epithelial
and mesenchymal markers. They utilised a fluorescence
RNA-ISH approach to quantify the proportion of epithelial
(E?), mesenchymal (M?) and hybrid (E/M) tumour cells
in; (i) epithelial and mesenchymal xenograft tumours
grown in mice, (ii) tissue microarrays containing samples
from both benign breast tissue and invasive primary breast
cancers, (iii) CTCs isolated from the blood of MBC
patients. One key observation of interest was that in
patients responding to therapy, a greater proportion of
CTCs switched to being E? post-treatment, whilst in non-
responders where disease progressed, the larger proportion
of CTC switched to being M? post-treatment.
This work has been supplemented by studies that have
provided some of the first direct evidence of EMP by
demonstrating the existence of EMP hybrids that harbour
tumour initiating properties in CTCs purified from the
blood of advanced prostate cancer patients [126] and
patients with non-small cell lung carcinoma [108]. More-
over, Wu et al. [134] applied an RNA-ISH approach to
CTCs isolated from a range of carcinoma patients and were
able to subcategorise them as being either epithelial,
mesenchymal, or hybrid. Based on the literature, studies
are still underway attempting to further demonstrate the
presence of the EMP hybrid cell, also described as meta-
stable, and its coexistence with the BCSC phenotype in
CTCs and DTCs [135, 136].
Evidence that CTCs are malignant cells
In 2000, a paper published by Pretlow et al. [137] provided
physical evidence that isolated CTCs could form tumours.
This was the first study to describe the establishment of
xenografts in nude mice from CTCs harvested from blood
of 14 patients with advanced treatment-resilient metastatic
cancer (11 prostate and 3 colon cancer patients). Lung
metastases were observed to develop in mice that received
CTCs from three of the patients (1 with colon and 2 with
prostate cancer). Subsequent work has since been pub-
lished illustrating that CTCs carry malignant characteris-
tics. In 2002, Fehm et al. [44] examined ‘circulating
epithelial cells’ (CEC) or ‘circulating epithelial tumour
cells’ (CETC), to determine whether they were aneu-
somic—contained aberrant chromosome copy numbers
relative to the normal diploid human cell—and compared
these aneusomic patterns to those from the matched pri-
mary tumour. The group was able to match the aneusomic
pattern of CEC and primary tumour touch samples in 10 of
13 patients, also noting gains of chromosomes were more
frequent than losses. In some cases the pattern of aneusomy
differed between CEC and primary tumour, reasons pro-
posed for this including; (i) shed CEC undergo further
genetic modifications, (ii) overlapping signals if more than
two copies are present, (iii) analysis in touch preparations
may have missed cells with matching aneusomic patterns
and (iv) the CEC were shed from a metastasis and not the
primary tumour. Additionally, further studies have
demonstrated the cancerous nature of CTCs, for example in
breast cancer patients that were found to overexpress the
proto-oncogene HER2 [138]. Epidermal growth factor
receptor, known to be frequently overexpressed in breast
cancers and correlated with a poor prognosis, has also been
detected on CTCs in 38 and 44 % of early and MBC
patients, respectively [139]. The tumourigenic and meta-
static potential of CTCs has been recently further demon-
strated and expanded upon using xenograft systems.
Baccelli et al. [140] successfully grafted CTCs from breast
cancer patients into the femoral medullary cavity of non
obese diabetic-severe combined immunodeficiency gamma
(NSG) mice—NSG mice lack mature lymphocytes, NK
cells, and have several compromised cytokine signalling
pathways in addition to an impaired innate response. They
noted that greater success was achieved when the isolated
CTCs were subject to FACS sorting for EpCAM, CD44,
CD47, and the proto-oncogene MET (a HGF receptor
tyrosine kinase). Whilst not all sorted CTCs were positive
for MET, the metastases that grew in mice were MET-
enriched. Hodgkinson et al. [141] were able to graft small
cell lung cancer CTCs following subcutaneous injection
into the flanks of NSG mice, and then confirmed that these
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tumours were derived from the isolated CTCs through
comparison of genomic profiles for TP53 and RB1. Yu
et al. [142] isolated CTCs from breast cancer patients and
were able to establish cells lines using non-adherent
in vitro culture, where it was noted that greater success of
cell line formation occurred using CTCs from patients who
were therapy-resistant. Successful xenografts were subse-
quently established from a portion of these cell lines in
NSG mice. Interestingly, Yu et al. [142] utilised these CTC
lines for the screening of mutations that would enable
targeting of drug sensitive pathways, of particular interest
were those that differed between the primary tumour and
CTCs, thus emphasising the importance of continual CTC
monitoring.
Cancer dissemination and dormancy
Is cancer dissemination an early event during tumouri-
genesis? The prevailing belief is that cancer arises from
an accumulation of genetic and epigenetic changes over
time, leading to cellular disorganisation and uncontrolled
growth, and that invasiveness only arises late in the
process after further changes. However emerging research
is revealing cancer dissemination can occur early in
cancer development [37, 143]. In mouse models, systemic
dissemination of tumour cells has been shown to occur
after early epithelial changes in the mammary gland [37].
Moreover, in both mouse and human, the number of
disseminated cells appears to be unrelated to the size of
the primary tumour [37, 144]. Research by Husemann
et al. [37] using two transgenic mouse models (HER2
transgenic mouse model—BALB-NeuT, and mouse
mammary tumour virus-polyoma middle T-antigen trans-
genic mouse model—MMTV-PyMT) demonstrated that
dissemination of tumour cells can occur in pre-invasive
stages of tumour progression and that the number and
genotype of seeded tumour cells were not associated with
tumour size. The highest dissemination rates have been
shown relative to the total number of cancer cells in the
primary tumour to occur early after transformation.
Interestingly, disruption of the basement membrane
underlying hyperplastic epithelia was observed in the
BALB-NeuT system. This was attributed to activation of
proteolytic systems in breast epithelia and found to be
associated with young age and atypical ductal hyperplasia
(ADH) following cDNA array analysis of microdissected
samples [37]. However, electron microscopy carried out
on both transgenic models, revealed that epithelial cells
were crossing the basement membrane prior to any indi-
cation of basement membrane degradation. In addition,
HER2? DTCs detected in the lung and bone marrow of
mice with ADH (a pre-malignant breast condition which
is not invasive), were confirmed to be malignant and by
comparative genomic hybridisation to have arisen from
the primary lesion [37].
In recent years it has also been demonstrated that dis-
seminated cancer cells often display a far less progressed
genomic state than would be expected if this original per-
ception of cancer metastasis were the case [145]. In a
review by Klein [145] the late dissemination model was
found to be incongruent with the timing of metastases
relative to their tumour of origin even when tumour volume
doubling time of primary tumour vs each metastases was
taken into consideration. Vogelstein et al. [146] speculated
in a review that perhaps there are no metastasis genes and
therefore the need for genetic and epigenetic aberrations to
accumulate over time is a void concept. It was suggested
that it may be a purely stochastic process depending on
which cells leave the tumour, where they go and when.
This statement is based on work demonstrating that normal
cells have been shown to survive and grow with functional
vasculature on lymph nodes, a common site of metastasis.
This work is complemented in a similar study by Podsy-
panina et al. [147] that demonstrated the ability of normal
mammary epithelial cells to survive in ectopic sites fol-
lowing injection into the circulation of mice and following
induced oncogene expression, to be able to multiply and
colonise the new sites. Klein subsequently reviewed this
publication and goes on to emphasise that the work high-
lights more than early vs late dissemination, but specifi-
cally whether malignant cells seen in a metastasis evolve
inside or outside the original tumour mass. The capacity for
early dissemination and implications of EMT in this were
highlighted in a recent study from Rhim et al. [148], where
fluorescence lineage labelling revealed the spread of pan-
creatic cancer cells prior to any histological or clinical
indications of a primary malignancy.
Dormancy of cancer cells that disseminated early from
primary tumour is thought to be the reason behind the
recurrence of cancer in individuals years or decades after a
successful primary tumour removal. Dormant cancer cells
may exist as quiescent solitary cells [149] or micrometas-
tases in a state of balanced proliferation [150] which are
not clinically apparent [151]. Like their DTC counterpart,
residual primary tumour cells are thought to employ dor-
mancy via similar mechanisms; quiescence, EMT, and
CSCs [152], all of which are discussed in this review.
Dormancy in the context of primary disease is likely to be
as a consequence of therapeutic intervention and may
indeed also apply to DTCs and micrometastases. In the
instance where treatment has yet to be initiated and occult
distant disease already exists, the driving cause of dor-
mancy is different—overcoming foreign microenvironment
pressure [153]. Schmidt-Kittler et al. [154] demonstrated
that disseminated cells found in the bone marrow of non-
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MBC patients harboured fewer and different genomic
aberrations than the primary tumour and suggested that
these seed cells must have spread before surgery or even
before first diagnosis. They go on to suggest that the rel-
atively small number of chromosomal aberrations in many
patients without overt metastases, but with disseminated
cells, may point to a deceleration of the carcinogenic
process in these cells, perhaps due to environmental con-
straints, which may account for dormancy. The length of
the period of dormancy may therefore reflect the time
necessary to accumulate further aberrations required for
unrestrained growth. These aberrations may differ sub-
stantially to those in the primary tumour, accounting for the
observed genetic differences seen between metastatic and
primary tumours [155]. There is evidence however that the
genetic profile of primary breast cancer can resemble that
of metastases [156], and this has been observed in other
types of cancer [157]. This suggests the early and late
independent progression models are not common and that
the capacity to metastasise either is or is not imprinted
within an entire tumour. How the relationship between
dormancy and mutation is modified in the clinical situation
with systemic treatments and treatment resistance is yet to
be determined, although some light has been shed on shifts
in circulating DNA patterns during the course of treatment
and site of distant metastasis [158].
CTCs/DTCs and ductal carcinoma in situ (DCIS)
Ductal carcinoma in situ (DCIS) is a non-invasive form of
breast cancer that involves the neoplastic proliferation of
tumour cells within the ductal-lobular structures of the
breast that have not invaded the ductal basement mem-
brane. Diagnosis of DCIS has increased dramatically in
recent years as a result of increased mammographic
screening and now represents up to 20 % of breast cancer
cases [159]. Although DCIS is classified on the basis of
histopathological criteria and growth dimensions/prognosis
may to some extent be predicted on this basis, much
remains to be understood regarding the behaviour of DCIS.
Whilst it has been widely assumed to have no metastatic
potential, patients are considered to have a relatively
increased risk of progression to invasive breast cancer and
of local recurrence particularly if the DCIS is of high
nuclear grade and overexpresses HER2 [159, 160]. Perhaps
surprisingly, up to 3 % of DCIS patients are found to have
axillary lymph node metastases [161]. This observation
coincides with the work by Husemann et al. [37], as dis-
cussed earlier, who demonstrated in mouse models that
tumour cells can disseminate from even the earliest
epithelial alterations, and so it appears that this may be the
case in at least some human DCIS patients. Sentinel node
involvement has been routinely reported in between 1 and
13 % of DCIS patients without evidence of invasion at the
primary site (although this of course could just be that the
invasive disease was not apparent in the sections reviewed
by the histopathologist). In a study of 266 patients diag-
nosed with DCIS, Banys et al. [162] identified DTCs in
bone marrow aspirates of 34 (13 %) patients. They found
no statistical correlation between the presence of DTCs and
clinicopathological features. Interestingly, whilst 3 of the
221 patients who underwent sentinel lymph node biopsy
were positive for tumour cells in the sentinel node, none of
these had DTCs in the bone marrow. However, a smaller
study by Sanger et al. [160] found that 4 of 19 (21.1 %)
patients with pure DCIS had detectable DTCs in their bone
marrow. Notably, they stress the need for the use of
appropriate antibodies to detect all DTCs, including those
that may have undergone an EMT and are not detectable by
commonly used CK antibodies. They propose that the
13 % DTC detection rate reported by Husemann et al. [37]
may be misleadingly low due to the antibody used. Banys
et al. [162] also used the same CK antibodies, which may
potentially explain their similar findings. The clinical
weight of these early metastatic events in the context of
DCIS is still ambiguous. While sentinel lymph node
metastasis is detected in 3–4 % of DCIS patients, the rate
of overt distant metastasis in the patients is low [163].
Further, given that tumour stage is an independent negative
prognostic indicator [164], the rate of effective dissemi-
nation in early lesions is unclear. Thus the role of MRD
detection in predicting the prognosis of DCIS patients is
still of unknown clinical significance but is an exciting area
of future translational study.
MRD and the CSC phenotype
CSCs were first described in the context of leukaemia,
when Bonnet et al. [165] reported that only a minor subset
of leukemic cells with the CD34?CD38- cell surface
marker profile, when transplanted into SCID mice, resulted
in dissemination and survival with leukemic cell mor-
phology similar to that seen in the donor patient. Putative
CSCs have since been identified in a range of solid
tumours, including; breast, colon, brain and prostate [110,
166–168]. In studies of MRD it is known that CTC and
DTC populations are very heterogeneous, even within the
same patient, for example morphologically [169] as well as
molecularly [170]. This is also true of cancer cells within
the primary tumour, as alluded to earlier in this review.
There is growing evidence suggesting that only certain
subpopulations of primary tumour cells acquire the char-
acteristics necessary to break away from the primary site
and enter the circulation and it is increasingly proposed that
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only certain subpopulations of ‘aggressive’ CTCs/DTCs
are able to progress into metastases. Along these lines,
CTCs capable of short term culture were found to better
predict outcome than patients without culturable CTCs
[133]. The concept of CSCs implies that there is a small
population of cells within a primary tumour that have the
propensity to be tumourigenic and multipotent, hence
CSCs provide a possible explanation as to what this sub-
population of cells is comprised of and how it has the
capacity to propagate cancer progression.
In breast cancer these putative CSCs were originally
identified by Al-Hajj et al. as CD44?CD24-/low through
the use of xenotransplantation experiments [110]. Studies
indicate they make up approximately 10–20 % of tumour
cells in the primary mass, although the degree of variation
is extensive [171, 172]. CD44 is a cell adhesion molecule
that has been associated with stem cells in normal breast
tissue but is also found on many other cell types. It has
been reported that CD44 potentiates the adhesion of breast
cancer cells to endothelial cells in the bone marrow [173],
thus possibly mediating bone-specific metastasis. CD24 is
normally expressed during the early stages of B cell
development and is not usually expressed in adult human
tissues but has been demonstrated in human cancers. In
breast cancer cell lines, CD24 expression reduces stromal
cell-derived factor-1-mediated migration and signalling via
CXCR4, suppressing their metastatic potential, whilst
CD24-/low cells have conversely been shown to increase
metastatic potential [171]. In subsequent studies, an addi-
tional candidate marker for the CSC phenotype has been
utilised—ALDH1, which was originally identified in the
context of retinoblastoma [174], and is involved in the
oxidation of intracellular aldehydes and is highly expressed
in many stem and progenitor cells [111, 113, 175]. This
marker has since been incorporated in methods used for the
detection and assessment of MRD both molecularly [114,
116] and visually [176, 177].
There is a substantial body of work indicating that EMP
plays a role in the development of cancer cells harbouring
traits that define a CSC [113, 178–180]. Thus there is
mounting focus on and evidence for the possibility that
CSC subpopulations of either the primary tumour or CTCs/
DTCs, at least partly through EMP, acquire CSC attributes
such as quiescence, self-renewal, asymmetric division and
multi-drug resistance [56, 114, 116, 132], as well as an
inherent resistance to radiation [181]. These characteristics
allow the cells not only to survive in hostile environments
such as the circulatory system and bone marrow, but to also
survive conventional therapies and subsequently drive
tumour growth and the establishment of metastases. It is
important to acknowledge that the CSC concept is still
under much debate [182, 183]. Work from the Weinberg
lab showed that BCSC could be derived from differentiated
mammary cells [184], whilst Liu et al. [185] revealed that
the CD24-/CD44hi subpopulation was distinct from the
ALDH1? subpopulation in BCSCs, thus questioning the
use of these together to define the putative BCSC pheno-
type. Moreover, Sarrio et al. [186] demonstrated stem-like
attributes in normal-like breast cancer cell lines indepen-
dent of mesenchymal state. The consequence of studies
such as these is that the complexity of the relationship
between EMP and BCSC is either greater than current
comprehension, or that its validity is questionable. Partic-
ularly interesting articles have called into question the
validity of xenotransplantation as a measure of tumouri-
genicity when investigating these CSCs [187, 188], dis-
cussing whether these cells really are responsible for
tumour propagation is questioned as examples of leukae-
mia are given where cells not sorted for CSC markers are
still able to form tumours from low starting numbers. There
is concern over this point of argument as it compares
findings in solid carcinomas to systems using non-solid
cancers. However, similar work demonstrating the
tumourigenic capacity of melanoma cells using low num-
bers of unsorted cells in NSG mice has also been published
[189, 190]. Despite all this, the key observation that has
remained consistent is that these particular ‘CSC’ sub-
populations, whether or not they are actually stem-like, are
substantially more aggressive in that they persist after
treatment and have a greater tumourigenic capacity.
Characterisation of CTCs/DTCs
CTCs are typically found in extremely low frequencies,
being as few as 1 per 109 blood cells or 1 per 106–107
mononuclear cells [191–193]. However, CTCs/DTCs are
often much larger than blood cells, with the mean diameter
of tumour cells in the blood of breast cancer patients
reported as 29.8–33.9 lm [194], whilst the vast majority of
blood leukocytes are 8–12 lm. According to one publica-
tion, the basic morphological criteria for CTC include a
nucleus larger than 16 lm, irregularity of the nuclear
contour, the presence of visible cytoplasm and a nuclear-to-
cytoplasmic (N/C) ratio greater than 0.8 [192]. Whilst
some of these criteria are commonly shared by other
studies, it is worth noting that the exact cut-off values can
vary, and alternative criteria such as anisonucleosis may be
utilised [195]. DTCs share these characteristics, as well as
being reported to have a tendency to occur in cell clusters,
with strong or irregular cytoplasmic CK staining, visible
CK filaments, a large nucleolus and often a granular or
stippled nucleus [196, 197]. Having described these mor-
phological characteristics, one group has published work
related to CTCs displaying morphological features
heterogeneous in nature. CTCs were observed to have an
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N/C ratio that spanned from high to low and that their
overall size varied from being larger to smaller than white
blood cells (WBC). Further comparisons were made
between the morphology of CTCs and primary/metastatic
tumour from the same patient. A key conclusion was that
CTCs maintain primary tumour cytology characteristics
and are representative of the heterogeneous nature of the
primary/metastatic tumours. Their results argued against
the hypothesis that only particular subsets of carcinoma
cells have the capacity to disseminate, such as CSCs [169,
198].
In 2007, the American Society of Clinical Oncology
(ASCO) breast cancer consensus panel assessed the use of
prospective markers in breast cancer for various purposes.
Some of the approved included; Cancer antigen 15-3 (CA
15-3) and Cancer antigen 27.29 (CA 27.29) kits that
measure Mucin 1 (MUC1) levels in peripheral blood,
assessment of carcino-embryonic antigen (CEA) levels in
blood and ER, PgR, HER2 status of the primary tumour.
Markers that lacked sufficient evidence for approval
included DNA/ploidy via flow cytometry, p53 and the
presence/absence of CTCs/DTCs [199]. The promise
behind CTCs/DTCs with respect to their use in the clinic is
that they provide a potential source of repetitive low-in-
vasive ‘liquid’ biopsies that allows for continual ‘real-time’
monitoring of cancer patients that are at risk of relapse
[200]. The reasoning behind the decision on CTCs/DTCs
by the ASCO was the observation that not every patient
found to be positive for these cells would necessarily
relapse as expected. Several interventional trials have been
established to measure the clinical utility of CTC enu-
meration [201], and despite confirming a strong prognostic
relationship between CTC burden and therapeutic
response, the SWOG S0500 trial could not demonstrate
clinical utility in the form of increased overall survival
(OS) or progression free survival (PFS) in patients who
were put on alternative chemotherapeutic regimens due to
persistent or increased CTC counts following initial ther-
apy [202]. The more intensive CirCe01 trial is ongoing,
and interim analysis has recently confirmed the strong
prognostic power of CTCs [203]. Consequently, there has
been an increasing amount of work attempting to charac-
terise CTCs/DTCs molecularly and phenotypically in order
to identify MRD that poses a true threat by gaining an
understanding of the underlying biology. As a result, one
key observation, which has been repeatedly shown, is that
CTCs/DTCs are very heterogeneous. Efforts to characterise
MRD are greatly hampered, not only by scarcity, but by the
variety and specificity of the various enrichment and
detection methods employed by different laboratories. This
aspect has been previously reviewed in a number of articles
[204–208].
As EMP may be an essential process in the generation
and function of CTCs and DTCs, multiple publications
have attempted to assess EMP-related markers both
molecularly and phenotypically, as discussed earlier. It
may partly be through this very process that the large
variation in the presence of molecular markers arises and
can be seen on CTCs/DTCs. Additionally, if the notion that
EMP has a critical role in MRD holds true, then a number
of technical implications could well be responsible for
variation in results as alluded to earlier. The key ramifi-
cation relates to the fact that to date a large proportion of
enrichment and detection methods have relied on the
expression of epithelial markers, principally EpCAM and
CKs such as CK8, CK18 and CK19. In fact this has been
the case for decades, for example some of the earliest work
utilising EpCAM and CK18 as a means of detecting DTCs
was performed by Kubuschok et al. [209] in 1999 and
Schlimok et al. [210] in 1987. Therefore, because these can
be downregulated or lost during EMT, there is potentially a
bias in the molecular and phenotypic characteristics
reported thus far. It has certainly been demonstrated that
some subtypes of breast cancer are under-represented in
MRD characterisation studies, again due to lack of
epithelial markers [211]. One way that groups have
attempted to circumvent this problem is to employ multi-
marker approaches both in the enrichment step and the
detection process [212–218].
These studies, and many others, have highlighted the
variations in molecular and phenotypic expression of their
selected markers between individual CTCs/DTCs, even
within the same patient. For example, the study performed
by Strati et al. [219] demonstrated high heterogeneity in
CTC gene expression in both early breast cancer (EBC)
and MBC. They found that in EBC patients nearly half
were positive for CK19 and TWIST1, whilst approximately
20 % or less were positive for melanoma-associated anti-
gen 3 (MAGE-A3), HER2, human telomerase reverse
transcriptase (hTERT) and human mammaglobin (hMAM).
When they looked in MBC patients, roughly 50 % were
positive for CK19, 40 % for TWIST1, 30 % for hMAM and
20 % or less for MAGE-A3, HER2 and hTERT. Conse-
quently, because this diversity in MRD has been repeatedly
witnessed, a new mindset on how to investigate these cells
has evolved. As a result, methods embracing approaches
towards MRD that capture the individual cell, specifically
in regards to molecular analyses, are being utilised. To our
knowledge, Powel et al. [170] was the first group to isolate
single CTCs from breast cancer patients for subsequent
downstream analysis with a high throughput molecular
assay. Sixty-five blood samples from 50 breast cancer
patients, both EBC and MBC, were subjected to an in-
house CTC enrichment device, the MagSweeper. They
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isolated 510 cells with a pipette guided by microscopy and
the RNA from each subjected to a nested RT-qPCR
approach using the Fluidigm system. Of the 510 cells, 105
were confirmed as CTCs according to their set parameters,
and of the 87 genes assessed only 31 were considered
‘consistently’ detectable in at least 15 % of analysed CTCs.
Two major subgroups of expression were identified irre-
spective of patient, and neither of which was consistent
with the profiles of different breast cancer cell line sub-
groups. This study provides an indication of the extent of
variation occurring between CTCs of different patients as
well as within the same patient, in addition to the sparse
nature of expression of some molecular markers in MRD.
Early studies focusing on DTCs have provided insight
into characteristics of functional benefit such as the
downregulation of major histocompatibility complex
(MHC) class I expression, which has been suggested to
provide an advantage by evading cytotoxic T-cell mediated
cell death. Using an IHC approach, pioneering work by
Pantel et al. [220] identified isolated tumour cells within
the bone marrow of both breast and stomach/colon cancer
patients lacking MHC I expression. This was noted to be
more frequent in the breast cases as opposed to the stom-
ach/colon cases and attributed to the tendency of breast
cancers to preferentially develop overt metastases in bone.
It was also noted that a mixture of MHC class I positivity
and negativity was seen within 13 % of patients, thus
reinforcing the heterogeneous nature of these cells. A sta-
tistically significant correlation between incidence of MHC
I negative DTCs and a poorly differentiated primary
tumour was observed and also confirmed in a separate
study [221]. This latter study also demonstrated a poorer
prognostic outcome in patients with MHC I negative
DTCs. Similar work investigating uPAR expression in
individual DTCs of breast cancer patients has also been
performed following the original work by Heiss et al. [222]
in gastric carcinoma. In addition to ICC, Pierga et al. [223]
isolated EpCAM positive DTCs and subjected them to
qRT-PCR for relative expression analysis of uPAR mRNA.
They found that while not all patients had uPAR? DTCs,
of those that did, half had high uPAR mRNA levels. These
DTCs with high uPAR expression significantly correlated
with respect to their presence in patients with more
aggressive cancers, for example 5 out of 6 patients with
HER2? cancer had high levels of uPAR in their DTCs.
The association between uPAR? DTCs in patients with
aggressive primary cancer has also been observed in the
context of prostate carcinoma [224]. In addition to the
known tissue remodelling function of plasminogen acti-
vation via uPAR, alternative pathway activation (e.g. ERK/
MAPK, HER2, FAK, Src) also contributes to metastasis-
promoting phenotypes such as cell division and migration
[225], thus providing a reasonable explanation for the
observations of uPAR in DTCs. Work that first assessed
ICAM-1 expression by DTCs was performed by Passlick
et al. [226] who found that most NSCLC patients with an
ICAM-1-ve tumour had DTCs that remained ICAM-1-ve,
while a larger proportion of patients with ICAM-1?ve
tumours switched to ICAM-ve DTCs, and that it was the
patients with ICAM-1-ve DTCs that tended to have worse
outcome. However, it was the work by Tsujisaki et al.
[227] describing elevated serum ICAM-1 levels in malig-
nant cancer patients that set the precedent for the study
directly assessing ICAM-1 status on DTCs. Passlick et al.
[228] then performed a correlative study assessing MHC I
and ICAM-1 status in NSCLC tumours in relation to lymph
node metastasis and bone marrow DTC positivity. It was
found that reduced/absent MHC I expression correlated
significantly with lymph node metastases as did a lack of
ICAM-1 expression. The lack of ICAM-1 expression pro-
vides an interesting mechanism of survival by reducing
monocyte and T-cell mediated destruction. However, this
particular study did not directly assess ICAM-1 status in
either the lymph node metastases or the DTCs, and no
correlation was found between MHC I/ICAM-1 negativity
and DTC positivity in bone marrow. Surprisingly, even
though a role for ICAM-1 in DTCs has been described and
considered for some time, there is still a lack of work
directly assessing its expression in the context of metastasis
and prognostic outcome across a range of carcinomas.
Recent work has turned to applying higher throughput
genetic techniques to DTCs in order to collectively identify
potentially key genomic alterations, but just as importantly,
to demonstrate the applicability of such techniques to
DTCs and therefore the prospect of using said methods as
part of routine analysis of MRD. Holcomb et al. [229]
applied an array comparative genomic hybridisation
(aCGH) technique to DNA from small numbers of 10-20
DTCs isolated from the bone marrow of prostate cancer
patients and identified losses in 8p23, 10q, 13q, and 16q,
while copy number gains were seen in 8q. While the
authors describe these changes as typical of prostate can-
cer, some affected genes such as CDH8 and CDH11 pro-
vide interesting avenues of investigation across a range of
carcinomas. This aCGH method was further refined in a
subsequent study comparing copy number variations
(CNVs) in primary breast cancer to matched single DTCs
using higher resolution single cell aCGH [230]. CNVs
were observed to correlate between the primary tumour and
DTCs, including losses at 8p, 11q, and gains at 1q, 8q and
17q. The results of this study appear to support the
sequential clonal evolution theory of cancer, and yet sim-
ilar work in breast cancer revealed discordant CNVs
between matched primary cancer and DTCs [231], sug-
gestive of the parallel progression/CSC model. Moller et al.
[232] expanded on this approach by the inclusion of single
534 Clin Exp Metastasis (2016) 33:521–550
123
cell next generation sequencing, thereby enabling not only
CNV detection by aCGH, but also the ability to confirm
CNVs and the capacity to detect copy-neutral loss of
heterozygosity (cnLOH). Analysis was carried out on two
cases of matched primary breast cancer and DTCs; the first
revealed highly concordant genomic aberrations between
tumour and DTC including monosomy 4, deletions on
chromosomes 6, 16, 17, and duplications on chromosomes
1 and 17. The second on the other hand revealed a number
of observations in DTC that were either sub-clonal in the
tumour or absent altogether, such as a gain in 16p that was
sub-clonal, trisomy 21 that was absent in the primary, and
cnLOH of an allele on chromosome 13 that was present as
a sub-clonal deletion in the tumour. Despite the mixed
picture seen in the results of investigations into the beha-
viour of CTCs/DTCs, some overlapping data has provided
insight into the potential importance of EMP, CSCs and the
mechanisms they potentially help regulate such as; motil-
ity, invasion, therapy resistance, dormancy and cell sur-
vival by proliferation, modulation of senescence, or
possibly anti-apoptosis.
Oestrogen and progesterone receptor status
in MRD
It is currently standard practice to determine the patho-
logical grade and stage of the primary tumour and to
examine HRs including ER alpha (ERa) and PgR using
IHC. Tumours that are identified as HR positive have been
shown to have a better prognosis in terms of overall sur-
vival, while HR negative tumours appear to have a more
aggressive phenotype [233, 234]. Moreover, the presence
of HRs in cancers provides a therapeutic target and allows
the use of anti-oestrogen drugs improving survival for
women with these tumours. However, many ERa? tumours
develop either de novo or acquired hormone resistance and
thus progress to metastases even with anti-endocrine ther-
apies. It has long been observed that the ERa and/or PgR
status of the metastatic tissue may be discordant with that
of the primary tumour [235–237], with ERa? but PgR-
breast tumours comprising the poorer-prognosis Luminal B
subtype.
Concordance rates between the primary and metastatic
tissue have been found to be as low as 46 % and both the
gain and loss of each HR has been demonstrated in
metastases relative to the primary tumour [237–239]. The
therapeutic impact of HR discordance was illustrated in a
recent publication, where it was observed that HR?
patients who went on to relapse with HR- metastases have
significantly worse outcome [240]. Interestingly, patients
that are HR- at primary diagnosis but relapse as HR? have
better outcome than patients who have a HR- recurrence
irrespective of their original primary tumour HR status
[241]. This and multiple other studies have led to specu-
lation that patients with HR? metastases, who had a HR-
primary tumour, may benefit from endocrine therapy, but
as yet there has been no prospective randomised trial
analysing the impact on survival of biopsy-driven treat-
ment [242]. There have been some discrepancies in the
reported rate of gain or loss of ERa and PgR expression in
metastases relative to the primary tumour. Amir et al. [243]
report that in a study on MBC patients, 12.4 % patients
with an ERa? primary tumour had ERa- metastases, whilst
13.2 % of patients with an ERa- primary tumour had ERa?
metastases, indicating a similar level of gain or loss of the
oestrogen receptor. However, in the same patient group,
42.7 % of PgR? primary tumour patients had PgR-
metastases, whilst 16.0 % of PgR- primary tumour
patients had PgR? metastases, indicating a greater loss than
gain of PgR expression in metastatic tissue. Nishimura
et al. [244] report a drop in both ERa and PgR expression
from primary to metastatic tissue, with ERa and PgR levels
dropping from 63.9 to 56.7 % respectively in primary
tumour, to 57.7 and 43.3 % respectively in metastases. The
implication of this work as a whole is the potential for
repeated biopsies in order to individually manage a
patient’s therapy regimen by either giving the option to
partake in a treatment which may be beneficial, or to
withdraw from a treatment plan that is doing more harm
than good. However, major limitations of assessing HR
status in this manner relate to cost, time and invasiveness
and so MRD has become the potential alternative source of
information in this regard.
Given the role of CTCs/DTCs in the progression to
metastases, and their persistence in patients after surgery
and adjuvant therapy, it is unsurprising that the HR status
of CTCs/DTCs has also been investigated and found in
many instances to differ to that of the primary tumour.
What may be surprising is that the discordance between
primary tumour and CTCs HR status appears to be much
greater than that seen between primary and metastatic tis-
sue. Aktas et al. [114] found that in 87 CTC? MBC
patients, 77 % of those with ERa? tumours had ERa-
CTCs and 87 % of those with PgR? tumours had PgR-
CTCs. Concordance rates for ERa and PgR were 41 and
45 % respectively, and they observed that most CTCs were
ERa- and PgR- (81 and 90 % respectively). A separate
study by Fehm et al. [245], examining CTCs in primary
breast cancer patients, found concordance rates between
ERa and PgR status of CTCs and primary tumour to be 29
and 25 % respectively. Whilst DTCs were also isolated and
detected in this study by IHC targeting epithelial CKs, no
subsequent analysis of ERa or PgR status was performed
on the DTCs. Another study assessing CTCs in MBC
patients during the course of therapy also compared HR
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status of CTCs to patient pathology data. They found that
45 % of patients with ERa? primary tumours had ERa-
CTCs, whilst 78 % of patients with PgR? primary tumours
had PgR- CTCs [246]. Nadal et al. [247] expanded on
these preceding studies by investigating HR status in CTCs
compared to primary tumours and found that discordance
was once again present, in this instance at greater propor-
tions with respect to PgR. Perhaps their most intriguing
finding however related to the observation that hetero-
geneity in HR status was seen within individual patients
who bore both HR? and HR- CTCs.
When examining DTCs in primary breast cancer
patients, Fehm et al. [248] found that there was a concor-
dance rate of 28 % between the ERa status of the primary
tumour and DTCs. Despite 88 % of patients having an
ERa? primary tumour, only 12 % of DTCs overall were
ERa?, and as was the case with CTCs in the study by Nadal
et al. [247], ERa expression was determined to be hetero-
geneous in 10 of 38 (26 %) patients with more than one
DTC. They reported only one instance where a patient had
an ERa- primary tumour but ERa? DTCs. This discor-
dance between DTCs and primary tumour had been pre-
viously illustrated in a study by Ditsch et al. [249], who
found that only 18 % of patients with ERa? primary cancer
had ERa? DTCs. It is suggested by studies with such
findings that the lack of ERa expression on CTCs and
DTCs may be due to the clonal heterogeneity of the pri-
mary tumour [245, 248], in addition to the more aggressive
and invasive features of ERa- cells [250, 251].
Patients with ERa- primary tumours typically have a
worse prognosis than patients with ERa? tumours and thus
it may be that within heterogeneous tumours, the more
aggressive and invasive ERa- cells have increased likeli-
hood of dissemination. As discussed earlier, it has been
proposed that subpopulations of MRD with tumour initi-
ating properties share characteristics reflective of an EMT
signature and may be CSCs. In support of this, it has been
demonstrated that a loss of ERa expression coincides with
and may induce, EMT. Oestrogen receptor silencing of the
ERa? non-invasive MCF7 breast cancer cell line via
siRNA resulted in oestrogen/tamoxifen-resistant cells that
had altered morphology, increased motility, a switch from
a CK to a vimentin-based cytoskeleton and increased
invasive properties [252, 253]. It was also noted that key
transcriptional factors that drive EMT were upregulated in
these cells. Guttilla et al. [254] were able to demonstrate
the loss of ERa in MCF7 cells that were subject to pro-
longed 3D culture conditions, as upon returning the cells to
standard 2D culture, they were enriched in EMT and CSC
characteristics. These studies coincide with work suggest-
ing that ERa can stimulate GATA3 expression and drive
FOXA1 co-expression, both of which oppose EMT [255],
and work from our own lab showing that the transcription
factor c-Myb, which mediates the pro-proliferative effects
of oestrogen in breast cancer cells, has a reciprocal, inverse
role on suppressing the EMT driver Zeb1, and is itself
transcriptionally suppressed by Zeb1 [256]. Therefore a
potential role for the silencing of ERa exists in the invasive
and metastatic processes, in turn providing a lead as to
which CTCs/DTCs might be of greater concern. Unfortu-
nately, to date there appears to be no studies published that
directly compare ERa and PgR status on primary and
metastatic tissue, as well as CTCs and DTCs. Results from
studies such as those mentioned above would indicate that
whilst ERa and PgR expression seems to be largely lost in
CTCs and DTCs, it is regained to some extent in metastatic
tissue.
HER2 status: differences in primary tumour,
MRD and metastases
Amplification of the growth factor receptor HER2 gene and
subsequent overexpression of HER2 occurs in approxi-
mately 12 % of primary breast cancers. Tumour cells that
are HER2? have an advanced extravasative potential that
results in an aggressive form of the disease that is often
resistant to many cytotoxic drugs and is associated with
significantly decreased disease-free survival (DFS) and OS
[138, 197, 257]. In recent years a monoclonal antibody to
HER2 known as trastuzumab (Herceptin, Genentech) has
become available and proven very effective in treating
patients with HER2 positive tumours. Trastuzumab binds
to HER2, blocking the growth-stimulating intracellular
signalling, decreasing cellular repair mechanisms follow-
ing chemo- and radio-therapy and possibly improving
apoptotic capacity [258]. However, eligibility for treatment
with trastuzumab is usually based entirely on the HER2
status of the primary tumour. Further, studies have shown
that less than half of patients with an overexpression of
HER2 in the primary tumour respond to trastuzumab,
whether given alone or in combination with chemotherapy
[258]. Newer HER2 blockers such as lapatinib and per-
tuzumab are being used in conjuction with trastuzumab and
proving beneficial in clinical trials [259, 260].
As with HR status, many recent studies have demon-
strated that HER2 status differs between primary and
metastatic tumours [197, 261]. Liedtke et al. [239] report a
discordance of 13.6 % between primary and metastatic
tissue, which is similar to the 14.4 % reported by Nishi-
mura et al. [244]. Amir et al. [243] however, report only a
5.5 % discordance rate, though notably they demonstrate a
greater loss than gain of HER2 expression, with 12.5 % of
HER2? primary tumour patients having HER2- metas-
tases. Interestingly, a study by Carlsson et al. [258]
examining HER2 status in the primary tumour and lymph
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nodes of 47 patients with distant metastases, found no
‘drastic’ changes in HER2 expression (i.e. change sufficient
enough to alter HER2 status classification). Unfortunately
the HER2 status of the distant metastases was not obtained
as part of the investigation [258]. There is also the sug-
gestion that HER2 status may change during treatment.
This is exemplified in a study by Apostolaki et al. [262],
who assessed a cohort of 214 early stage breast cancer
patients and found that 8 of 161 prechemotherapy HER2-
patients had become HER2? following treatment, which
was associated with a worse DFS. The functional signifi-
cance of these observations are brought home by the
finding that a number of patients treated with and
responding to trastuzumab were found in a subsequent
centralised review to be false positive for HER2 in the
primary tumour, suggesting that their disseminated disease
may have gained HER2 expression [263]. Importantly,
some were found to respond to the HER2-targeted therapy.
Issues exist here in regards to long term therapy deci-
sions being based on primary tumour pathology, as well as
issues associated with performing repeated biopsies of
metastases, as described in the preceding section. Once
again MRD provides a possible alternative method for
patient monitoring and treatment planning. It has been seen
in CTCs/DTCs, similarly to HR status, that a greater dis-
cordance is observed in the HER2 status when compared
with the primary tumour. Fehm et al. [245] report HER2
discordance of 47 %, which is substantially lower than that
seen for the HRs, but remains significantly higher than that
seen between primary and metastatic tissue. The discor-
dance of HER2 status between CTCs and primary tumour
has been demonstrated in other work, which also indicates
that the phenomenon of heterogeneity between CTCs
within individual patients, in regards to HER2, also exists
as it does for ERa/PgR [264, 265].
This discordance in HER2 expression between primary
tumour and MRD has clinical significance, as a study by
Apostolaki et al. [262] demonstrated that the presence of
HER2 mRNA in CTCs enriched from patient blood after
they had undergone adjuvant chemotherapy was associated
with decreased DFS. Multivariate statistical analysis in the
study revealed that the detection of HER2? CTCs was an
independent negative prognostic factor in relation to DFS.
Wulfing et al. [266] were able to demonstrate this prior to
the above study, however in addition to a reduced DFS they
also found an association with reduced OS. It was the work
of Wasserman et al. [267] that set up the technical foun-
dation for the development of a PCR platform for the
assessment of HER2 status in MRD, on which the afore-
mentioned studies were subsequently developed. There
have been a number of publications since assessing HER2
status in CTCs compared to the primary tumour and the
persistence of these cells during treatment and its relation
to poor outcome [268, 269]. HER2? DTCs have been
demonstrated to be more common in MBC patients when
compared to non-metastatic patients irrespective of pri-
mary tumour HER2 status, and like their CTC counterpart
these cells have been found to correlate with worse prog-
nostic outcome [270, 271]. These publications by Pantel
et al. [270] and Braun et al. [271] make the inference that
the subset of DTCs that behave this way was due to; (i) the
role of HER2 in modulating cell surface adhesion mole-
cule-extracellular matrix interactions, and (ii) variable
response to chemotherapeutic agents at least partly due to
being in an indolent state of growth. As a consequence, the
clinical implication is that this subset of cells contributes to
the initial metastasis of breast cancer but also poses a risk
of relapse following treatment and thus is an ideal target.
The effectiveness of targeting the HER2 antigen with
trastuzumab on residual CTCs/DTCs that are resilient to
standard systemic therapy post-surgery has been demon-
strated [272]. Currently there is a randomised clinical trial
underway in Europe (DETECT III trial), where women
with HER2 negative advanced breast cancer bearing HER2
positive CTCs/DTCs are sorted into either a standard
treatment group or a group that receives lapatinib in
addition to standard care. This is now being run in con-
junction with the DETECT IV trial, whereby anti-mitotic
therapies are to be tested within the same cohort of
recruited patients. Another European clinical trial is
underway, recruiting women with HER2 negative primary
breast cancer who have persistent CTCs even after sys-
temic therapy and surgery (TREAT-CTC trial). The
patients are allocated into a standard care group, or a group
that receives trastuzumab in addition to standard care. The
aforementioned publications and trials are great examples
of how work involved in the characterisation of CTCs/
DTCs has helped identify patient populations at greater risk
and also opened avenues for therapeutic intervention
depending on the behaviour of these cells in a given
patient.
Survival mechanisms: platelet clumping, immunity
and circulating tumour microemboli
Platelet clumping
CTCs have been shown to form aggregates with platelets in
the blood and this may confer several mechanisms of
survival and increased metastatic potential [273, 274]. The
effects of the interaction between CTCs and platelets are
reciprocal; CTCs stimulate platelet aggregation and also
excrete factors that activate platelets whilst activated pla-
telets secrete growth factors, which in turn impact tumour
growth and extravasation of CTCs or circulating tumour
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microemboli (CTM) [273, 274]. Platelets may provide a
physical ‘cloak’ for the tumour cells, preventing access by
immune cells that would destroy them. Furthermore the
CTC and platelet aggregation is thought to confer protec-
tion for the CTCs against the high shear forces which occur
in the blood [274]. Studies have also shown that platelets,
activated by their aggregation with CTCs, secrete soluble
factors including TGFb, which downregulates the expres-
sion of NKG2D (natural killer group 2, member D), the
activating immunoreceptor of natural killer (NK) cells,
thereby impairing their immune function [275–277]. It has
been suggested by studies in animal models that anti-pla-
telet therapy may reduce the rate of metastases [275, 278].
The study by Yu et al. [133], as mentioned in a previous
section, implicated the transforming growth factor beta
(TGFb) signalling pathway in their study of the
metastable phenotype on CTCs, which is known to play a
role in EMT. Therefore the research regarding platelet-
mediated TGFb stimulation of CTCs provides a candidate
explanation for the occurrence of EMP in MRD, and is
supported by observations from Labelle et al. [279] of
platelet induced EMT being mediated by TGFb and NF-
jB. Additionally, the interaction between CTCs and
endothelial cells, which may play a role in the extravasa-
tion of CTCs at metastatic sites, is also facilitated by pla-
telet attachment to CTCs [280].
Immunity
Multiple studies have assessed CTC/DTC counts several
times over the course of systemic therapy, such as that by
Hayes et al. [281], and it has been generally noted that
patients with persistent MRD following therapy are more
likely to have worse outcome [202, 282, 283]. This asso-
ciation has been reinforced by the single biggest study on
prognostic outcome relative to CTC counts in non-meta-
static breast cancer patients undergoing chemotherapy;
patients who were CTC positive before therapy had worse
OS, DFS, distant DFS, and breast cancer-specific survival.
Meta-analyses on both CTCs [284] and DTCs [46] have
demonstrated the independent negative prognostic value of
CTC/DTC counts. Moreover, there has been work sug-
gesting that in addition to the value of the presence/number
of CTCs/DTCs, the dynamics of change in CTC burden
over the course of therapy is also important [285]. One
interpretation of this data is possibly that the detrimental
effects of rigorous chemo- and radio-therapies on a
patient’s immune system could contribute towards MRD
survival via an immunosuppressive function. Having stated
this, given that declines in CTC numbers have also been
seen following therapy and are associated with better out-
come, substantiating this claim becomes difficult. Further,
work by Muller et al. [286] revealed that patients that went
into remission following therapy were not necessarily
consistently positive for CTCs, in fact most were either
always negative or positive during only a single follow-up
test, although the exact dynamics of when the positive
result occurred and any technical limitations do need to be
considered. However, in theory the interaction between
platelets and MRD that potentially occurs alongside and/or
drives an EMT, supplemented by systemic therapies, may
contribute towards evasion of immune surveillance and
promote immunosuppression. Intriguingly, it has been
shown under culture conditions that cancer cells swiftly
interact with platelets in a bid to transfer host MHC class I
molecules onto their surface, effectively masking them and
enabling evasion of NK cells, as well as the potential to
disrupt T-cell mediated acquired immunity [287]. Knutson
et al. [288] undertook a study that also demonstrated the
persistence of cancer cells that underwent immuno-editing.
They attempted to grow the mouse mammary carcinoma
(MMC) cell line, originally derived from HER2 transgenic
mice, in Friend leukaemia virus 1b (FVB/N) parental mice
and found after some time that a more resilient immuno-
edited population arose, which was determined to have
gained a mesenchymal phenotype. Considering the impli-
cation of this EMT, its association with immuno-editing,
the occurrence of immuno-editing following interaction
with platelets, as well as platelet-derived TGFb-driven
EMT; it should be noted that SNAIL-mediated EMT has
been shown to induce immunosuppression through altered
expression of immunoreactive epitopes [289]. Hence it
may be that immuno-editing by cancer cells occurs
alongside that which is happening with platelets, both of
which cumulatively push EMP, the result being enhanced
immune suppression and evasion.
Circulating tumour microemboli
Although the extent of study on this phenomenon is
extremely limited, it has been reported that CTCs can exist
as clumps of contiguous cells in the circulation, which have
recently been named CTM—or ‘CTC clusters’. The earliest
research to demonstrate CTMs in clinical patients was
performed on blood samples from colorectal cancer
patients [290], which was only preceded by studies in
animal models [291, 292]. Molnar et al. [290] found that
CTCs can indeed persist in clusters or doublets of cells that
were either entirely CK positive or a mixture of CK? and
CK- cells. This was followed by Marrinucci et al. [169],
who were investigating the morphologic heterogeneity of
CTCs in a MBC patient and also noted the presence of
CTC clusters. Their observations coincided with those by
the Molnar group in regards to the clusters containing a
mixture of cells, but moreover that the CTCs within these
clusters displayed variation in their size and morphology
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[169]. Subsequent to this, Cho et al. [293] expanded on
preceding work by investigating CTMs in a range of
metastatic epithelial cancers and found at least one cluster
in approximately 50 % of breast and lung cancer patients,
22 % of pancreatic cancer patients and 93 % of prostate
cancer patients. These clusters are proposed to have sur-
vival and proliferative advantages over single CTC in the
circulation [280]. A study by Hou et al. [294] examining
CTCs, apoptotic CTCs and CTMs in small-cell lung can-
cer, found that apoptotic CTCs ranged from 0.2 to 20 % of
overall CTC numbers but that none of the cells comprising
CTMs exhibited apoptotic morphology. They also
demonstrated that although the cell proliferation marker
Ki67 expression was detected in a portion of solitary CTCs
from patient samples, all CTMs were negative for Ki67, a
finding that was also seen in a separate study on NSCLC by
the same group [295]. They found that CTMs when
injected into mice, demonstrated a higher metastatic
potential than solitary CTCs. They suggest that the absence
of apoptotic cells and of proliferating cells within CTMs
give the clusters a survival advantage, protecting them
from anoikis and making them relatively resistant to
chemotherapy and radiotherapy [294]. Most recently,
Aceto et al. [296] showed that CTMs were oligoclonal, and
thus derived from the primary tumour, and that their
presence in the blood of breast cancer patients correlated
with poorer OS and PFS.
Perspectives
The potential role of CTCs and DTCs (which together with
therapy resilient cancer cells are collectively termedMRD) in
the clinical setting is progressing towards the possibility of
being used as part of routine care. CTCs in particular provide
anexciting ‘liquidbiopsy’ prospect as blood sample collection
is bothminimally invasive and very quick, providing access to
disseminating cancer cells. In either instance, the idea that
these cells can provide an important genomic guide to the
disseminated disease, and can be monitored at regular inter-
vals during the course of cancer treatment would allow for
constant, up-to-date, optimised and personalised treatment
planning and strategies. For example, the advance in short
term culture of CTCs using recentmethods showed that it was
possible in*80 % ofMBC cases and*40 % of EBC cases,
potentially allowing some drug assessment alongside patient
treatment [297]. Whilst the presence of MRD, as well as its
persistence during the course of systemic therapy, has yielded
associations with worse prognostic outcome, to date evidence
of clinical utility is insufficient to warrant routine investiga-
tion of MRD during standard clinical care as assessed by the
ASCO and SWOG S0500 study [199, 202]. The CirCe-01
clinical utility trial in France is ongoing, having also shown
strong prognostic power of CTC enumeration as an initial
finding [203]. What is clear is that CTCs and DTCs can be
different from one another, both between patients and within
the same patient, and this provides explanation as to why
variable outcomes have been observed amongst patients
positive for CTCs/DTCs, which was a key issue identified by
the ASCO consensus panel [199]. Thus advancing our
knowledgeon the biologyof these cells has become the central
focal point and the key to their application. Whilst great
technical challenges exist in this realm of research, much has
still come forth aboutMRD in a relatively short period of time
relating to aspects such as; heterogeneity, discordance with
primary tumour and metastasis, EMT, CSCs, therapy resis-
tance, survival, behaviour with neighbouring cells and the
microenvironment, aswell as changes in our understanding on
the nature ofmetastasis. The advances that have beenmade in
our understanding of CTCs and DTCs in the last two decades
in unprecedented; there are more than 20,000 publications in
Medline on CTCs alone. The prognostic relationship between
CTC presence/enumeration by numerous methodologies,
nonemore robust than the Veridex CellSearch system despite
its reliance on epithelial perseverance, is undeniable, and new
horizons in terms of diagnostics and therapeutic targeting is
strongly compelling. So in order for MRD to progress into the
realm of routine clinical practice, several areas must (and are
currently) be addressed; (i) work characterising the molecular
and phenotypic behaviour of MRD must continue in order to
reliably identify subpopulations of cells that are truly
responsible for disease progression in carcinoma patients that
otherwisewould simply be deemed ‘‘CTC/DTCpositive’’, (ii)
evidence of benefit towards patient care with respect to ther-
apeutic management must be demonstrated through identifi-
cation of dangerous MRD subpopulations over the course of
treatment—this may soon be the case upon completion of the
CirCe-01, DETECT III/IV and TREAT-CTC trials, (iii) the
approach used to isolate and identify CTCs/DTCs must
become globally standardised—there are currently a vast
range of techniques and parameters used identifyCTCs/DTCs
[196, 298–301], and (iv) a rapid and reliable method of
expansion of MRD must be developed for the testing and
identification of effective chemotherapeutic agents. Applying
all these advances in knowledge and technique would allow
for administration of the most useful medication while
avoiding unnecessary exposure of the patient to ineffective
drugs, all in a timely and universal fashion.
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